Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers.

Kopečná M, Macháček M, Nováčková A, Paraskevopoulos G, Roh J, Vávrová K.

Sci Rep. 2019 Oct 10;9(1):14617. doi: 10.1038/s41598-019-51226-5.

2.

Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model.

Xu H, Muise ES, Javaid S, Chen L, Cristescu R, Mansueto MS, Follmer N, Cho J, Kerr K, Altura R, Machacek M, Nicholson B, Addona G, Kariv I, Chen H.

J Cell Mol Med. 2019 Oct;23(10):7063-7077. doi: 10.1111/jcmm.14608. Epub 2019 Aug 26.

3.

4-Methylcatechol, a Flavonoid Metabolite with Potent Antiplatelet Effects.

Applová L, Karlíčková J, Warncke P, Macáková K, Hrubša M, Macháček M, Tvrdý V, Fischer D, Mladěnka P.

Mol Nutr Food Res. 2019 Jul 25:e1900261. doi: 10.1002/mnfr.201900261. [Epub ahead of print]

PMID:
31343835
4.

Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4.

Griffiths K, Binder U, McDowell W, Tommasi R, Frigerio M, Darby WG, Hosking CG, Renaud L, Machacek M, Lloyd P, Skerra A, Foley M.

MAbs. 2019 Oct;11(7):1331-1340. doi: 10.1080/19420862.2019.1626652. Epub 2019 Aug 23.

5.

Red-Emitting Fluorescence Sensors for Metal Cations: The Role of Counteranions and Sensing of SCN- in Biological Materials.

Lochman L, Machacek M, Miletin M, Uhlířová Š, Lang K, Kirakci K, Zimcik P, Novakova V.

ACS Sens. 2019 Jun 28;4(6):1552-1559. doi: 10.1021/acssensors.9b00081. Epub 2019 May 30.

PMID:
31094188
6.

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab.

Voors-Pette C, Lebozec K, Dogterom P, Jullien L, Billiald P, Ferlan P, Renaud L, Favre-Bulle O, Avenard G, Machacek M, Plétan Y, Jandrot-Perrus M.

Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964. doi: 10.1161/ATVBAHA.118.312314.

PMID:
31017822
7.

Elevated O-GlcNAcylation enhances pro-inflammatory Th17 function by altering the intracellular lipid microenvironment.

Machacek M, Saunders H, Zhang Z, Tan EP, Li J, Li T, Villar MT, Artigues A, Lydic T, Cork G, Slawson C, Fields PE.

J Biol Chem. 2019 May 31;294(22):8973-8990. doi: 10.1074/jbc.RA119.008373. Epub 2019 Apr 22.

PMID:
31010828
8.

Binding of an amphiphilic phthalocyanine to pre-formed liposomes confers light-triggered cargo release.

Macháček M, Carter KA, Kostelanský F, Miranda D, Seffouh A, Ortega J, Šimůnek T, Zimčík P, Lovell JF.

J Mater Chem B. 2018 Nov 28;6(44):7298-7305. doi: 10.1039/C8TB01602J. Epub 2018 Aug 22.

PMID:
30984399
9.

Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials.

Reimerová P, Stariat J, Bavlovič Piskáčková H, Jansová H, Roh J, Kalinowski DS, Macháček M, Šimůnek T, Richardson DR, Štěrbová-Kovaříková P.

Anal Bioanal Chem. 2019 Apr;411(11):2383-2394. doi: 10.1007/s00216-019-01681-w. Epub 2019 Mar 1.

PMID:
30820631
10.

Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro.

Vicen M, Vitverova B, Havelek R, Blazickova K, Machacek M, Rathouska J, Najmanová I, Dolezelova E, Prasnicka A, Sternak M, Bernabeu C, Nachtigal P.

FASEB J. 2019 May;33(5):6099-6114. doi: 10.1096/fj.201802245R. Epub 2019 Feb 12.

PMID:
30753095
11.

Fluorescent Penetration Enhancers Reveal Complex Interactions among the Enhancer, Drug, Solvent, and Skin.

Kopečná M, Kováčik A, Kučera O, Macháček M, Sochorová M, Audrlická P, Vávrová K.

Mol Pharm. 2019 Feb 4;16(2):886-897. doi: 10.1021/acs.molpharmaceut.8b01196. Epub 2019 Jan 24.

PMID:
30629452
12.

How to become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence in Breast Cancer (CCB2).

Montagna G, Anderson D, Bochenek-Cibor J, Bozovic-Spasojevic I, Campos C, Cavallero S, Durutovic I, Gomez Cuadra MO, Irfan T, Joly L, Kassem L, Kolben TM, Machacek M, Mir Khan B, Nagvekar M, Pellegrino B, Pogoda K, Câmara GR, Ferreira PS, Seferi M, Talibova N, Van den Rul N, Vettus E, Rocco N.

Breast. 2019 Feb;43:18-21. doi: 10.1016/j.breast.2018.10.006. Epub 2018 Oct 22.

13.

Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.

Stachel SJ, Egbertson MS, Wai J, Machacek M, Toolan DM, Swestock J, Eddins DM, Puri V, McGaughey G, Su HP, Perlow D, Wang D, Ma L, Parthasarathy G, Reid JC, Abeywickrema PD, Smith SM, Uslaner JM.

Bioorg Med Chem Lett. 2018 Apr 1;28(6):1122-1126. doi: 10.1016/j.bmcl.2018.01.039. Epub 2018 Feb 10.

PMID:
29534798
14.

O-GlcNAc: a novel regulator of immunometabolism.

Machacek M, Slawson C, Fields PE.

J Bioenerg Biomembr. 2018 Jun;50(3):223-229. doi: 10.1007/s10863-018-9744-1. Epub 2018 Feb 6. Review.

15.

Male-to-female aggression in cage-housed common pheasants (Phasianus colchicus) during the breeding season was not related to male plasma testosterone level.

Zapletal D, Macháček M, Suchý P, Straková E, Vitula F.

Br Poult Sci. 2018 Jun;59(3):256-263. doi: 10.1080/00071668.2018.1436159. Epub 2018 Mar 6.

PMID:
29393676
16.

Sustained O-GlcNAcylation reprograms mitochondrial function to regulate energy metabolism.

Tan EP, McGreal SR, Graw S, Tessman R, Koppel SJ, Dhakal P, Zhang Z, Machacek M, Zachara NE, Koestler DC, Peterson KR, Thyfault JP, Swerdlow RH, Krishnamurthy P, DiTacchio L, Apte U, Slawson C.

J Biol Chem. 2017 Sep 8;292(36):14940-14962. doi: 10.1074/jbc.M117.797944. Epub 2017 Jul 24.

17.

Galactosyl Pentadecene Reversibly Enhances Transdermal and Topical Drug Delivery.

Kopečná M, Macháček M, Prchalová E, Štěpánek P, Drašar P, Kotora M, Vávrová K.

Pharm Res. 2017 Oct;34(10):2097-2108. doi: 10.1007/s11095-017-2214-3. Epub 2017 Jun 29.

PMID:
28664316
18.

Phthalocyanines and Tetrapyrazinoporphyrazines with Two Cationic Donuts: High Photodynamic Activity as a Result of Rigid Spatial Arrangement of Peripheral Substituents.

Ghazal B, Machacek M, Shalaby MA, Novakova V, Zimcik P, Makhseed S.

J Med Chem. 2017 Jul 27;60(14):6060-6076. doi: 10.1021/acs.jmedchem.7b00272. Epub 2017 Jun 14.

PMID:
28558213
19.

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.

Krause A, Machacek M, Lott D, Hurst N, Bruderer S, Dingemanse J.

CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):477-485. doi: 10.1002/psp4.12202. Epub 2017 May 27.

20.

First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.

Keilholz U, Rohde L, Mehlitz P, Knoedler M, Schmittel A, Kümmerlen V, Klinghammer K, Treasure P, Lassus M, Steventon G, Machacek M, Utku N.

Eur J Cancer. 2017 Jul;80:14-25. doi: 10.1016/j.ejca.2017.03.032. Epub 2017 May 19.

PMID:
28531881
21.

Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents.

Němeček J, Sychra P, Macháček M, Benková M, Karabanovich G, Konečná K, Kavková V, Stolaříková J, Hrabálek A, Vávrová K, Soukup O, Roh J, Klimešová V.

Eur J Med Chem. 2017 Apr 21;130:419-432. doi: 10.1016/j.ejmech.2017.02.058. Epub 2017 Feb 28.

PMID:
28279848
22.

Dodecyl Amino Glucoside Enhances Transdermal and Topical Drug Delivery via Reversible Interaction with Skin Barrier Lipids.

Kopečná M, Macháček M, Prchalová E, Štěpánek P, Drašar P, Kotora M, Vávrová K.

Pharm Res. 2017 Mar;34(3):640-653. doi: 10.1007/s11095-016-2093-z. Epub 2017 Jan 9.

PMID:
28070753
23.

Medication Adherence in 13- to 24-Year-Old Youth Living With HIV.

Chenneville T, Machacek M, St John Walsh A, Emmanuel P, Rodriguez C.

J Assoc Nurses AIDS Care. 2017 May - Jun;28(3):383-394. doi: 10.1016/j.jana.2016.11.002. Epub 2016 Nov 11.

PMID:
27931753
24.

Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.

Hašková P, Jansová H, Bureš J, Macháček M, Jirkovská A, Franz KJ, Kovaříková P, Šimůnek T.

Toxicology. 2016 Sep 14;371:17-28. doi: 10.1016/j.tox.2016.10.004. Epub 2016 Oct 12.

25.

Tetra(3,4-pyrido)porphyrazines Caught in the Cationic Cage: Toward Nanomolar Active Photosensitizers.

Machacek M, Demuth J, Cermak P, Vavreckova M, Hruba L, Jedlickova A, Kubat P, Simunek T, Novakova V, Zimcik P.

J Med Chem. 2016 Oct 27;59(20):9443-9456. Epub 2016 Oct 5.

26.

Reduced O-GlcNAcase expression promotes mitotic errors and spindle defects.

Lanza C, Tan EP, Zhang Z, Machacek M, Brinker AE, Azuma M, Slawson C.

Cell Cycle. 2016 May 18;15(10):1363-75. doi: 10.1080/15384101.2016.1167297.

27.

Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.

Jansová H, Bureš J, Macháček M, Hašková P, Jirkovská A, Roh J, Wang Q, Franz KJ, Kovaříková P, Šimůnek T.

Toxicology. 2016 Mar 28;350-352:15-24. doi: 10.1016/j.tox.2016.03.004. Epub 2016 Apr 1.

28.

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites.

Potůčková E, Roh J, Macháček M, Sahni S, Stariat J, Šesták V, Jansová H, Hašková P, Jirkovská A, Vávrová K, Kovaříková P, Kalinowski DS, Richardson DR, Šimůnek T.

PLoS One. 2015 Oct 13;10(10):e0139929. doi: 10.1371/journal.pone.0139929. eCollection 2015.

29.

Heteroatom-substituted tetra(3,4-pyrido)porphyrazines: a stride toward near-infrared-absorbing macrocycles.

Vachova L, Machacek M, Kučera R, Demuth J, Cermak P, Kopecky K, Miletin M, Jedlickova A, Simunek T, Novakova V, Zimcik P.

Org Biomol Chem. 2015 May 28;13(20):5608-12. doi: 10.1039/c5ob00651a. Epub 2015 Apr 17.

PMID:
25881971
30.

Far-red-absorbing cationic phthalocyanine photosensitizers: synthesis and evaluation of the photodynamic anticancer activity and the mode of cell death induction.

Machacek M, Cidlina A, Novakova V, Svec J, Rudolf E, Miletin M, Kučera R, Simunek T, Zimcik P.

J Med Chem. 2015 Feb 26;58(4):1736-49. doi: 10.1021/jm5014852. Epub 2015 Feb 4.

PMID:
25599409
31.

Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.

Potůčková E, Hrušková K, Bureš J, Kovaříková P, Špirková IA, Pravdíková K, Kolbabová L, Hergeselová T, Hašková P, Jansová H, Macháček M, Jirkovská A, Richardson V, Lane DJ, Kalinowski DS, Richardson DR, Vávrová K, Šimůnek T.

PLoS One. 2014 Nov 13;9(11):e112059. doi: 10.1371/journal.pone.0112059. eCollection 2014.

32.

Nonradioactive glycosyltransferase and sulfotransferase assay to study glycosaminoglycan biosynthesis.

Ethen CM, Machacek M, Prather B, Tatge T, Yu H, Wu ZL.

Methods Mol Biol. 2015;1229:431-41. doi: 10.1007/978-1-4939-1714-3_33.

PMID:
25325970
33.

Decisional capacity among youth with HIV: results from the MacArthur Competence Tool for Treatment.

Chenneville T, Machacek M, Tan R, Lujan-Zilberman J, Emmanuel P, Rodriguez C.

AIDS Patient Care STDS. 2014 Aug;28(8):425-32. doi: 10.1089/apc.2013.0374. Epub 2014 Jul 7.

PMID:
24999924
34.

Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.

Jansová H, Macháček M, Wang Q, Hašková P, Jirkovská A, Potůčková E, Kielar F, Franz KJ, Simůnek T.

Free Radic Biol Med. 2014 Sep;74:210-21. doi: 10.1016/j.freeradbiomed.2014.06.019. Epub 2014 Jun 30.

35.

Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.

Potuckova E, Jansova H, Machacek M, Vavrova A, Haskova P, Tichotova L, Richardson V, Kalinowski DS, Richardson DR, Simunek T.

PLoS One. 2014 Feb 20;9(2):e88754. doi: 10.1371/journal.pone.0088754. eCollection 2014.

36.

Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Vavrova A, Jansova H, Mackova E, Machacek M, Haskova P, Tichotova L, Sterba M, Simunek T.

PLoS One. 2013 Oct 7;8(10):e76676. doi: 10.1371/journal.pone.0076676. eCollection 2013.

37.

Water-soluble non-aggregating zinc phthalocyanine and in vitro studies for photodynamic therapy.

Makhseed S, Machacek M, Alfadly W, Tuhl A, Vinodh M, Simunek T, Novakova V, Kubat P, Rudolf E, Zimcik P.

Chem Commun (Camb). 2013 Dec 11;49(95):11149-51. doi: 10.1039/c3cc44609c.

PMID:
24040651
38.

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.

Br J Dermatol. 2013 Feb;168(2):402-11. doi: 10.1111/bjd.12112.

PMID:
23362969
39.

Quantitative imaging of epithelial cell scattering identifies specific inhibitors of cell motility and cell-cell dissociation.

Loerke D, le Duc Q, Blonk I, Kerstens A, Spanjaard E, Machacek M, Danuser G, de Rooij J.

Sci Signal. 2012 Jul 3;5(231):rs5. doi: 10.1126/scisignal.2002677.

40.

Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays.

Prather B, Ethen CM, Machacek M, Wu ZL.

Anal Biochem. 2012 Apr 1;423(1):86-92. doi: 10.1016/j.ab.2012.01.003. Epub 2012 Jan 17.

PMID:
22289690
41.

Protein kinase A governs a RhoA-RhoGDI protrusion-retraction pacemaker in migrating cells.

Tkachenko E, Sabouri-Ghomi M, Pertz O, Kim C, Gutierrez E, Machacek M, Groisman A, Danuser G, Ginsberg MH.

Nat Cell Biol. 2011 Jun;13(6):660-7. doi: 10.1038/ncb2231. Epub 2011 May 15.

42.

Universal phosphatase-coupled glycosyltransferase assay.

Wu ZL, Ethen CM, Prather B, Machacek M, Jiang W.

Glycobiology. 2011 Jun;21(6):727-33. doi: 10.1093/glycob/cwq187. Epub 2010 Nov 15.

PMID:
21081508
43.

Update on lymphocyte specific kinase inhibitors: a patent survey.

Martin MW, Machacek MR.

Expert Opin Ther Pat. 2010 Nov;20(11):1573-93. doi: 10.1517/13543776.2010.517749. Epub 2010 Sep 10. Review.

PMID:
20831362
44.

Protrusion and actin assembly are coupled to the organization of lamellar contractile structures.

Lim JI, Sabouri-Ghomi M, Machacek M, Waterman CM, Danuser G.

Exp Cell Res. 2010 Aug 1;316(13):2027-41. doi: 10.1016/j.yexcr.2010.04.011. Epub 2010 Apr 18.

45.

Coordination of Rho GTPase activities during cell protrusion.

Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, Abell A, Johnson GL, Hahn KM, Danuser G.

Nature. 2009 Sep 3;461(7260):99-103. doi: 10.1038/nature08242. Epub 2009 Aug 19.

46.

Prenyltransferase substrate binding pocket flexibility and its application in isoprenoid profiling.

Xiao Y, Machacek M, Lee K, Kuzuyama T, Liu P.

Mol Biosyst. 2009 Sep;5(9):913-7. doi: 10.1039/b902370d. Epub 2009 Mar 26.

PMID:
19668852
47.

N-benzylsalicylthioamides: highly active potential antituberculotics.

Dolezal R, Waisser K, Petrlíková E, Kunes J, Kubicová L, Machácek M, Kaustová J, Dahse HM.

Arch Pharm (Weinheim). 2009 Feb;342(2):113-9. doi: 10.1002/ardp.200800032.

PMID:
19137534
48.

Antileukotrienic phenethylamido derivatives of arylalkanoic acids in the treatment of ulcerative colitis.

Junek R, Kverka M, Jandera A, Panajotová V, Satinský D, Machácek M, Kuchar M.

Eur J Med Chem. 2009 Jan;44(1):332-44. doi: 10.1016/j.ejmech.2008.02.030. Epub 2008 Mar 7.

PMID:
18406012
49.

Cofilin activity downstream of Pak1 regulates cell protrusion efficiency by organizing lamellipodium and lamella actin networks.

Delorme V, Machacek M, DerMardirossian C, Anderson KL, Wittmann T, Hanein D, Waterman-Storer C, Danuser G, Bokoch GM.

Dev Cell. 2007 Nov;13(5):646-62.

Supplemental Content

Loading ...
Support Center